Related Experiment Video
Updated: Jul 17, 2026
06:34
Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
Published on: November 29, 2024
[Exenatide: use in humans].
Manuel Enrique Sierra-Ascencio1, Aurelio Ríos-Vaca, Alfredo Reza-Albarrán
1Departamento de Endocrinología y Metabolismo, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirdán, México D.F., México.
Gaceta Medica De Mexico
|January 5, 2007
Summary
Exenatide, a glucagon-like peptide-1 receptor agonist, offers a promising treatment for type 2 diabetes by improving glucose control and body weight. Its review covers efficacy and safety data from clinical trials.
Area of Science:
- Pharmacology
- Endocrinology
- Metabolic Diseases
Background:
- Type 2 diabetes is a growing global health concern.
- Current treatments have limitations in efficacy and side effects.
- Glucagon-like peptide-1 (GLP-1) receptor agonists represent a novel therapeutic class.
Purpose of the Study:
- To review the pharmacokinetics, pharmacodynamics, efficacy, and safety of exenatide.
- To consolidate data from early phase studies and clinical trials.
- To evaluate exenatide as a combination therapy for type 2 diabetes.
Main Methods:
- Literature review of phase I, II, and controlled clinical trials.
- Analysis of pharmacokinetic and pharmacodynamic data.
- Assessment of safety and efficacy profiles.
Main Results:
- Exenatide demonstrates significant effects on glucose metabolism, appetite, and body weight.
- Clinical trials confirm its efficacy as a combination therapy.
- Safety data from trials inform clinical use.
Conclusions:
- Exenatide is an effective therapeutic option for type 2 diabetes.
- Its multifaceted effects make it attractive for managing glucose and weight.
- Evidence supports its use in combination with other antidiabetic agents.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...